Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03991988 · ClinicalTrials.gov registry record · Phase 2
Montelukast Therapy on Alzheimer's Disease
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT03991988 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 32 participants.
The verdict
NCT03991988, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a one-year, double-blind placebo-controlled randomized clinical trial that compares montelukast to placebo in individuals with mild cognitive impairment (MCI) and early Alzheimer's disease (AD) dementia. The measures include cognitive function, cerebrospinal fluid (CSF) biomarkers and neuroimaging (cerebral perfusion and markers of vascular brain damage). Participants will be treated with montelukast (escalating doses:10, 20 to 40 mg) or matched placebo.
Interventions
- DRUG Montelukast
- DRUG Placebo oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03991988
The ClinicalTrials.gov registry entry for NCT03991988 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Montelukast is the first listed.
NCT03991988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03991988 about?
NCT03991988 is a clinical study titled "Montelukast Therapy on Alzheimer's Disease". This is a one-year, double-blind placebo-controlled randomized clinical trial that compares montelukast to placebo in individuals with mild cognitive impairment (MCI) and early Alzheimer's disease (AD) dementia. The measures include cognitive function, cerebrospinal fluid (CSF) biomarkers and neuroi...
What is the current status of trial NCT03991988?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2019-09-25. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT03991988?
The interventions under investigation include: Montelukast (DRUG), Placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT03991988?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.